Daily-Diary Evaluated Side-Effects of Conformal versus Conventional Prostatic Cancer Radiotherapy Technique

References

• Damber L, Johansson H, Gardfjäll O, Lenner P. National Board of Health and Welfare. Swedish Cancer Registry 1989
   Google Scholar
• Hanks G E, Schultheiss T E, Hunt M A, Epstein B. Factors influencing incidence of acute grade 2 morbidity in conformal and standard radiation treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1995; 31: 25–9
   PubMed Web of Science ®Google Scholar
• Bagshaw M A, Cox R S, Ray G R. Status of radiation treatment of prostate cancer at Stanford University. NCI Monogr 1988; 7: 47–60
   Google Scholar
• Coleman C N, Beard C J, Kantoff P W, Gelman R. Rate of relapse following treatment for localized prostate cancer. Int J Radiat Oncol Biol Phys 1994; 28: 303–13
   PubMed Web of Science ®Google Scholar
• Bagshaw M A. Potential for radiotherapy alone in prostatic cancer. Cancer 1985; 55: 2079–85
   PubMed Web of Science ®Google Scholar
• Asbell S A, Schlager B A, Baker A S. Revision of treatment planning for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1980; 6: 861–5
   PubMed Web of Science ®Google Scholar
• Sandler H M, McShan D L, Lichter A S. Potential improvement in the results of irradiation for prostate carcinoma using improved dose distribution. Int J Radiat Oncol Biol Phys 1992; 22: 361–7
   PubMed Web of Science ®Google Scholar
• Hanks G E, Diamond J J, Krall J M, Martz K L, Kramer S. A ten year follow-up of 682 patients treated for prostate cancer with radiation therapy in the United States. Int J Radiat Oncol Biol Phys 1987; 13: 499–505
   PubMed Web of Science ®Google Scholar
• Amdur R J, Parsons J T, Fitzgerald L T, Million R R. Adenocarcinoma of the prostate treated with external-beam radiation therapy: 5-Year minimum follow-up. Radiother Oncol 1990; 18: 235–46
   PubMed Web of Science ®Google Scholar
• Pilepich M V, Perez C A, Walz B J, Zivnuska F R. Complications of definitive radiotherapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1981; 7: 1341–8
   PubMed Web of Science ®Google Scholar
• Pilepich M V, Krall J M, Sause W T, et al. Correlation of radiotherapeutic parameters and treatment relatedmorbidity in carcinoma of the prostate—analysis of rtog study 75–06. Int J Radiat Oncol Biol Phys 1987; 13: 351–7
   PubMed Web of Science ®Google Scholar
• Pilepich M V, Asbell S O, Krall J M, Baerwald W H, Sause W T, Rubin P. Correlation of radiotherapeutic parameters and treatment related morbidity-analysis of RTOG Study 77–06. Int J Radiat Oncol Biol Phys 1987; 13: 1007–12
   PubMed Web of Science ®Google Scholar
• Gibbons R P, Mason J T, Correa R J, et al. Carcinoma of the prostate: local control with external beam therapy. J Urol 1979; 121: 310–12
   PubMed Web of Science ®Google Scholar
• Neglia W J, Hussey D H, Johanson D E. Megavoltage radiation therapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1977; 2: 873–82
   PubMed Web of Science ®Google Scholar
• Perez C A, Pilepich M V, Garcia D, Simpson J R, Zivnuska F, Hederman M A. Definitive radiation therapy in carcinoma of the prostate localized to the pelvis: experience at the Mallinckrodt Institute of Radiology. NCI Monogr 1988; 7: 85–94
   PubMedGoogle Scholar
• Pistenma D A, Ray G R, Bagshaw M A. The role of megavoltage radiation therapy in the treatment of prostatic carcinoma. Semin Oncol 1976; 3: 115–22
   PubMedGoogle Scholar
• Mameghan H, Fisher R, Mameghan J, Watt W H, Tynan A. Bowel complications after radiotherapy for carcinoma of the prostate: The volume effect. Int J Radiat Oncol Biol Phys 1990; 18: 315–20
   PubMed Web of Science ®Google Scholar
• Lawton C A, Won M, Pilepich M V, et al. Long-term treatment sequele following external beam irradiation for adenocarcinoma of the prostate: Analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 1991; 21: 935–9
   PubMed Web of Science ®Google Scholar
• Widmark A, Fransson P, Tavelin B. Self-assessment questionnaire for evaluating urinary and intestinal late side effects after pelvic radiotherapy in patients with prostate cancer compared with an age-matched control population. Cancer 1994; 74: 2520–32
   PubMed Web of Science ®Google Scholar
• Henriksson R, Franzn L, Littbrand B. Prevention of irradiation-induced bowel discomfort by sucralfate: a double-blind, placebo-controlled study when treating localized pelvic cancer. Am J Med 1991; 91(Suppl. 12A)151–7
   PubMed Web of Science ®Google Scholar
• Henriksson R, Franzán L, Littbrand B. Effects of sucralfate on acute and late bowel discomfort following radiotherapy of pelvic cancer. J Clin Oncol 1992; 10: 969–75
   PubMed Web of Science ®Google Scholar
• Soffen E M, Hanks G E, Hunt M A, Epstein B E. Conformal static field radiation therapy treatment of early prostate cancer versus non-conformal techniques: a reduction in acute morbidity. Int J Radiat Oncol Biol Phys 1992; 24: 485–8
   PubMed Web of Science ®Google Scholar
• Epstein B E, Hanks G E. Prostate cancer: evaluation and radiotherapeutic management. CA Cancer J Clin 1992; 42: 223–40
   PubMed Web of Science ®Google Scholar
• Sandler H M, McLaughlin P W, Ten Haken R K, Addison H, Forman J, Lichter A. Three dimensional conformal radiotherapy for the treatment of prostate cancer: low risk of chronic rectal morbidity observed in a large series of patients. Int J Radiat Oncol Biol Phys 1995; 33: 797–801
   PubMed Web of Science ®Google Scholar
• Valls A, Pestchen I, Prats C, Pera J, Aragon G, Vidarte M. Multicenter double blind randomized placebo controlled study to assess the effect of sucralfate in prevention of acute enteric toxicity secondary to pelvic irradiation. Meeting abstract presented at 5th UEGW congress, Paris, 1996
   Google Scholar
• Borghede G, Sullivan M. Measurement of quality of life in localized prostatic cancer patients treated with radiotherapy. Development of a prostate cancer-specific module supplementing the EORTC QLQ-C30. Qual Life Res 1996; 5: 212–22
   PubMed Web of Science ®Google Scholar
• Schultheiss T E, Hanks G E, Hunt M A, Lee W R. Incidence of and factors related to late complications in conformal and conventional radiation treatment of cancer of the prostate. Int J Radiat Oncol Biol Phys 1995; 32: 643–9
   PubMed Web of Science ®Google Scholar
• Leibel S A, Zelefsky M J, Kutcher G J, Burman C M, Mohan R, Mageras G S. The biological basis and clinical application of three-dimensional conformal external beam radiation therapy in carcinoma of the prostate. Semin Surg Oncol 1994; 21: 580–97
   Google Scholar
• Hanks G E. External-beam radiation therapy for clinically localized prostate cancer PCS National practice results of external beam radiation for prostate cancer. NCI Monogr 1988; 7: 75–84
   Google Scholar
• Lee W R, Hanks G E, Hanlon A L, Schultheiss T E, Hunt M A. Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: further evidence for a significant dose effect: see comments. Int J Radiat Oncol Biol Phys 1996; 35: 251–7
   PubMed Web of Science ®Google Scholar
• Vijayakumar S, Awan A, Karrison T, Culbert H, Chan S, Kolker J. Acute toxicity during external-beam radiotherapy for localized prostate cancer: comparison of different techniques: see comments. Int J Radiat Oncol Biol Phys 1993; 25: 359–71
   PubMed Web of Science ®Google Scholar
• Lennernäs B, Letocha H, Rikner G, Magnusson A, Nilsson S. External beam radiotherapy of localized prostatic adenocarcinoma. Acta Oncol 1995; 34: 953–8
   PubMed Web of Science ®Google Scholar